Literature DB >> 17135482

Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures.

Bruce I Turetsky1, Monica E Calkins, Gregory A Light, Ann Olincy, Allen D Radant, Neal R Swerdlow.   

Abstract

In an effort to reveal susceptibility genes, schizophrenia research has turned to the endophenotype strategy. Endophenotypes are characteristics that reflect the actions of genes predisposing an individual to a disorder, even in the absence of diagnosable pathology. Individual endophenotypes are presumably determined by fewer genes than the more complex phenotype of schizophrenia and would, therefore, reduce the complexity of genetic analyses. Unfortunately, despite there being rational criteria to define a viable endophenotype, the term is sometimes applied indiscriminately to characteristics that are deviant in affected individuals. Schizophrenia patients exhibit deficits in several neurophysiological measures of information processing that have been proposed as candidate endophenotypes. Successful processing of sensory inputs requires the ability to inhibit intrinsic responses to redundant stimuli and, reciprocally, to facilitate responses to less frequent salient stimuli. There is evidence to suggest that both these processes are "impaired" in schizophrenia. Measures of inhibitory failure include prepulse inhibition of the startle reflex, P50 auditory evoked potential suppression, and antisaccade eye movements. Measures of impaired deviance detection include mismatch negativity and the P300 event-related potential. The purpose of this review is to systematically evaluate the endophenotype candidacy of these key neurophysiological abilities. For each candidate, we describe typical experimental procedures, the current understanding of the underlying neurobiology, the nature of the abnormality in schizophrenia, the reliability, stability and heritability of the measure, and any reported gene associations. We conclude with a discussion of the few studies thus far that have employed a multivariate approach with these candidates.

Entities:  

Mesh:

Year:  2006        PMID: 17135482      PMCID: PMC2632291          DOI: 10.1093/schbul/sbl060

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  323 in total

1.  Saccadic disinhibition in schizophrenia patients and their first-degree biological relatives. A parametric study of the effects of increasing inhibitory load.

Authors:  C E Curtis; M E Calkins; W G Iacono
Journal:  Exp Brain Res       Date:  2001-03       Impact factor: 1.972

2.  A multivariate electrophysiological endophenotype, from a unitary cohort, shows greater research utility than any single feature in the Western Australian family study of schizophrenia.

Authors:  Gregory W Price; Patricia T Michie; Julie Johnston; Hamish Innes-Brown; Aaron Kent; Peter Clissa; Assen V Jablensky
Journal:  Biol Psychiatry       Date:  2005-12-20       Impact factor: 13.382

3.  Heritable features of the auditory oddball event-related potential: peaks, latencies, morphology and topography.

Authors:  S O'Connor; S Morzorati; J C Christian; T K Li
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1994-03

4.  The relationship between P300 amplitude and regional gray matter volumes depends upon the attentional system engaged.

Authors:  J M Ford; E V Sullivan; L Marsh; P M White; K O Lim; A Pfefferbaum
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1994-03

5.  Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia.

Authors:  Sherry Leonard; Judith Gault; Jan Hopkins; Judith Logel; Ruby Vianzon; Margaret Short; Carla Drebing; Ralph Berger; Diana Venn; Pinkhas Sirota; Gary Zerbe; Ann Olincy; Randal G Ross; Lawrence E Adler; Robert Freedman
Journal:  Arch Gen Psychiatry       Date:  2002-12

6.  Saccadic distractibility in first-episode schizophrenia.

Authors:  S B Hutton; E M Joyce; T R E Barnes; C Kennard
Journal:  Neuropsychologia       Date:  2002       Impact factor: 3.139

Review 7.  Behavioral and brain imaging studies of saccadic performance in schizophrenia.

Authors:  J E McDowell; B A Clementz
Journal:  Biol Psychol       Date:  2001 Jul-Aug       Impact factor: 3.251

8.  P300 subcomponent abnormalities in schizophrenia: I. Physiological evidence for gender and subtype specific differences in regional pathology.

Authors:  B I Turetsky; E A Colbath; R E Gur
Journal:  Biol Psychiatry       Date:  1998-01-15       Impact factor: 13.382

9.  Smooth pursuit and saccadic abnormalities in first-episode schizophrenia.

Authors:  S B Hutton; T J Crawford; B K Puri; L J Duncan; M Chapman; C Kennard; T R Barnes; E M Joyce
Journal:  Psychol Med       Date:  1998-05       Impact factor: 7.723

10.  P300 in first degree relatives of schizophrenics.

Authors:  Y Kidogami; H Yoneda; H Asaba; T Sakai
Journal:  Schizophr Res       Date:  1991-12       Impact factor: 4.939

View more
  207 in total

1.  Executive control in chronic schizophrenia: A perspective from manual stimulus-response compatibility task performance.

Authors:  Simone D Behrwind; Manuel Dafotakis; Sarah Halfter; Kerstin Hobusch; Mark Berthold-Losleben; Edna C Cieslik; Simon B Eickhoff
Journal:  Behav Brain Res       Date:  2011-04-14       Impact factor: 3.332

Review 2.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

3.  Distinct neural generators of sensory gating in schizophrenia.

Authors:  Terrance J Williams; Keith H Nuechterlein; Kenneth L Subotnik; Cindy M Yee
Journal:  Psychophysiology       Date:  2010-08-23       Impact factor: 4.016

4.  Antisaccade performance in schizophrenia patients, their first-degree biological relatives, and community comparison subjects: data from the COGS study.

Authors:  Allen D Radant; Dorcas J Dobie; Monica E Calkins; Ann Olincy; David L Braff; Kristin S Cadenhead; Robert Freedman; Michael F Green; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Gregory A Light; Sean P Meichle; Steve P Millard; Jim Mintz; Keith H Nuechterlein; Nicholas J Schork; Larry J Seidman; Larry J Siever; Jeremy M Silverman; William S Stone; Neal R Swerdlow; Ming T Tsuang; Bruce I Turetsky; Debby W Tsuang
Journal:  Psychophysiology       Date:  2010-04-05       Impact factor: 4.016

5.  Electroencephalography (EEG) and event-related potentials (ERPs) with human participants.

Authors:  Gregory A Light; Lisa E Williams; Falk Minow; Joyce Sprock; Anthony Rissling; Richard Sharp; Neal R Swerdlow; David L Braff
Journal:  Curr Protoc Neurosci       Date:  2010-07

6.  Neurocognitive and clinical dysfunction in adult Chinese, nonpsychotic relatives of patients with schizophrenia: Findings from the Changsha study and evidence for schizotaxia.

Authors:  William S Stone; Xiaolu Hsi; Liwen Tan; Shaochun Zhu; Lingjiang Li; Anthony J Giuliano; Larry J Seidman; Ming T Tsuang
Journal:  Asian J Psychiatr       Date:  2012-03

Review 7.  Imaging-genetics applications in child psychiatry.

Authors:  Daniel S Pine; Monique Ernst; Ellen Leibenluft
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-04-09       Impact factor: 8.829

8.  Modulation of sensorimotor gating in prepulse inhibition by conditional brain glycine transporter 1 deletion in mice.

Authors:  Philipp Singer; Detlev Boison; Hanns Möhler; Joram Feldon; Benjamin K Yee
Journal:  Eur Neuropsychopharmacol       Date:  2010-07-19       Impact factor: 4.600

9.  Increasing stimulus duration can normalize late-positive event related potentials in people with schizophrenia: Possible implications for understanding cognitive deficits.

Authors:  Bruce E Wexler; Satoru Ikezawa; Silvia Corbera
Journal:  Schizophr Res       Date:  2014-08-03       Impact factor: 4.939

Review 10.  Electrophysiological Endophenotypes for Schizophrenia.

Authors:  Emily M Owens; Peter Bachman; David C Glahn; Carrie E Bearden
Journal:  Harv Rev Psychiatry       Date:  2016 Mar-Apr       Impact factor: 3.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.